Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
Level V
Where this comes from
- Record sourced from PubMed, PMID 32331596.
- Also identified by DOI 10.1016/j.kint.2020.01.038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diabetes affects oxygen availability in the kidney, forcing the renal environment to rapidly and sustainably adapt. Physiological adaptations including activation of hypoxia inducible factor-1α and metabolic reprogramming toward pathways requiring less oxygen to maintain adenosine triphosphate production such as anaerobic glycolysis are impaired in the diabetic kidney. However, this study by Hasegawa et al. demonstrates renoprotection in diabetic kidney disease via the use of the hypoxia inducible factor-1α stabilizer enarodustat, opening a new therapeutic avenue to tackle these metabolic abnormalities.
Medical subject headings
- Diabetes Mellitus
- Diabetic Nephropathies
- Prolyl-Hydroxylase Inhibitors